151.37  -4 (-2.57%)		12-12 15:59
Open: 157.15 High: 157.15 Volume: 472,492		Pre. Close: 155.37 Low: 149.0701 Market Cap: 4,375(M)

Short term
Mid term
Targets	6-month :	199.57	1-year :	233.1
Resists	First :	170.86	Second :	199.57
Pivot price	159.95
Supports	First :	139.08	Second :	119.43
MAs	MA(5) :	157.21	MA(20) :	152.57
	MA(100) :	127.7	MA(250) :	0
MACD	MACD :	5.8	Signal :	7.2
%K %D	K(14,3) :	59.5	D(3) :	68.3
RSI	RSI(14): 51.5
52-week	High :	170.86	Low :	55.16

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ WGS ] has closed above bottom band by 10.2%. Bollinger Bands are 21.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	157.48 - 158.43	158.43 - 159.13
Low:	146.88 - 148.1	148.1 - 149
Close:	149.76 - 151.57	151.57 - 152.91

GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.

Sun, 14 Dec 2025
GeneDx Holdings Corp. (NASDAQ:WGS) Shares Could Be 40% Below Their Intrinsic Value Estimate - Yahoo Finance

Fri, 12 Dec 2025
Katherine Stueland Sells 3,639 Shares of GeneDx (NASDAQ:WGS) Stock - MarketBeat

Fri, 12 Dec 2025
BTIG Maintains GeneDx Holdings (WGS) Buy Recommendation - Nasdaq

Thu, 11 Dec 2025
GeneDx Holdings Corp.'s (NASDAQ:WGS) P/S Is On The Mark - 富途牛牛

Wed, 10 Dec 2025
Norges Bank Makes New Investment in GeneDx Holdings Corp. $WGS - MarketBeat

Tue, 09 Dec 2025
Legal & General Group Plc Increases Stake in GeneDx Holdings Corp. $WGS - MarketBeat

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Healthcare Information Services
Shares Out	29 (M)
Shares Float	21 (M)
Held by Insiders	12.2 (%)
Held by Institutions	104.9 (%)
Shares Short	3,610 (K)
Shares Short P.Month	3,000 (K)

EPS	0.11
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	10.11
Profit Margin	0.5 %
Operating Margin	-2.8 %
Return on Assets (ttm)	1.6 %
Return on Equity (ttm)	0.8 %
Qtrly Rev. Growth	51.9 %
Gross Profit (p.s.)	9.69
Sales Per Share	13.91
EBITDA (p.s.)	1.19
Qtrly Earnings Growth	0 %
Operating Cash Flow	33 (M)
Levered Free Cash Flow	33 (M)

PE Ratio	1261.41
PEG Ratio	0
Price to Book value	14.95
Price to Sales	10.87
Price to Cash Flow	131.8

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.